CRISPR Therapeutics AG (CRSP)
Automate Your Wheel Strategy on CRSP
With Tiblio's Option Bot, you can configure your own wheel strategy including CRSP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CRSP
- Rev/Share 0.4025
- Book/Share 20.9843
- PB 2.478
- Debt/Equity 0.1101
- CurrentRatio 16.2167
- ROIC -0.2678
- MktCap 4955610400.0
- FreeCF/Share -3.3201
- PFCF -16.3474
- PE -9.7233
- Debt/Assets 0.094
- DivYield 0
- ROE -0.2644
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CRSP | JP Morgan | -- | Overweight | -- | $70 | Sept. 18, 2025 |
| Upgrade | CRSP | Evercore ISI | In-line | Outperform | $60 | $99 | Feb. 14, 2025 |
| Upgrade | CRSP | TD Cowen | Sell | Hold | -- | $35 | Feb. 12, 2025 |
| Initiation | CRSP | H.C. Wainwright | -- | Buy | -- | $65 | Feb. 3, 2025 |
News
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive
CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock?
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive
CRISPR Therapeutics heads into Q4 earnings with rising Casgevy sales, collaboration revenues from Vertex, and a history of beating estimates.
Read More
CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Positive
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $51.31, denoting a +2.7% move from the preceding trading day.
Read More
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Positive
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Crispr Therapeutics: Patience And Opportunity Through Volatility
Published: January 14, 2026 by: Seeking Alpha
Sentiment: Positive
Crispr Therapeutics remains highly volatile, disconnected from near-term fundamentals, yet I see long-term value far above current levels. CRSP's business progress is slow, with pipeline milestones and cash runway—not quarterly EPS—being the most relevant metrics for investors. Key risks include the commercial ramp of Casgevy, pipeline execution, and surviving cash burn until anticipated profitability in 2028.
Read More
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
Published: January 13, 2026 by: Zacks Investment Research
Sentiment: Positive
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
CRISPR Therapeutics AG (CRSP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Published: January 12, 2026 by: Seeking Alpha
Sentiment: Neutral
CRISPR Therapeutics AG (CRSP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Read More
CRISPR Therapeutics (CRSP) Is Considered a Good Investment by Brokers: Is That True?
Published: January 12, 2026 by: Zacks Investment Research
Sentiment: Neutral
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read More
Crispr Therapeutics: Prospects For 2026 - Why I Believe Casgevy Is Key
Published: January 02, 2026 by: Seeking Alpha
Sentiment: Positive
Crispr Therapeutics AG commands a $5bn valuation, anchored by Casgevy's commercial approval and robust clinical data in SCD and TDT. Casgevy's slow commercial ramp is expected to accelerate in 2026, with revenue and patient growth as key valuation drivers. CRSP's pipeline—spanning in-vivo, CAR-T, and diabetes assets—offers major upside, but Casgevy remains the only revenue source.
Read More
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock
Published: December 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
Read More
CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Negative
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $56.46, marking a -2.5% move from the previous day.
Read More
CRSP Stock Rises on Encouraging Early Data From Zugo-Cel Studies
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Positive
CRISPR Therapeutics shares jump after early zugo-cel study data show sustained B-cell depletion and early efficacy across autoimmune and cancer studies.
Read More
CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies
Published: December 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
-Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the 100 million cell dose, with the first systemic lupus erythematosus (SLE) patient achieving Definitions of Remission in SLE (DORIS) remission through Month 6-
Read More
Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now?
Published: December 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
Read More
Why Is CRISPR Therapeutics (CRSP) Up 3.3% Since Last Earnings Report?
Published: December 10, 2025 by: Zacks Investment Research
Sentiment: Positive
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?
Read More
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Published: December 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy
Published: December 04, 2025 by: Seeking Alpha
Sentiment: Positive
Crispr Therapeutics AG remains a Strong Buy, driven by forthcoming revenue following Casgevy's FDA/EMA approvals and a robust, expanding pipeline targeting high-value indications. CRSP's commercial launch of Casgevy is progressing, with their share of a $100M+ 2025 total revenue expectation, and significant growth expected into 2026. The pipeline's cardiovascular assets (CTX310/320) show promising early efficacy, with huge addressable markets and the potential to disrupt standard-of-care regimens.
Read More
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
Published: November 25, 2025 by: Zacks Investment Research
Sentiment: Positive
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
4 Struggling Stocks With “Harmless” Pullbacks
Published: November 18, 2025 by: Schaeffers Research
Sentiment: Negative
Subscribers to Chart of the Week received this commentary on Sunday, November 16.
Read More
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Published: November 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
Read More
CRISPR Therapeutics Post Q3 Earnings: Testing Investor Patience, But Still A Buy
Published: November 13, 2025 by: Seeking Alpha
Sentiment: Positive
CRISPR Therapeutics AG remains a pioneering gene editing company, with Casgevy's slow commercial ramp and robust pipeline driving long-term potential. Despite Casgevy's $2.2M list price and broad approvals, revenue growth is gradual due to complex treatment logistics and patient adoption hurdles. CRSP's pipeline includes promising in-vivo cardiovascular, CAR-T oncology/autoimmune, and diabetes programs, with key updates expected in 2025.
Read More
CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates
Published: November 11, 2025 by: Zacks Investment Research
Sentiment: Negative
CRISPR Therapeutics posts a narrower-than-expected Q3 loss, trims R&D spend, and advances late-stage and next-gen gene-editing programs.
Read More
CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Negative
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.32. This compares to a loss of $1.01 per share a year ago.
Read More
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
Published: October 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
Read More
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
Read More
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock
Published: October 07, 2025 by: Zacks Investment Research
Sentiment: Positive
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
CRSP & Sirius Begin Dosing in Thromboembolic Disorder Study in EU
Published: September 23, 2025 by: Zacks Investment Research
Sentiment: Neutral
CRISPR Therapeutics and Sirius dose the first patient in a phase II study of SRSD107 for thromboembolic disorders in Europe.
Read More
Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now?
Published: September 23, 2025 by: Zacks Investment Research
Sentiment: Positive
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Published: September 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Wall Street Analysts See CRISPR Therapeutics (CRSP) as a Buy: Should You Invest?
Published: September 11, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
About CRISPR Therapeutics AG (CRSP)
- IPO Date 2016-10-19
- Website https://www.crisprtx.com
- Industry Biotechnology
- CEO Samarth Kulkarni
- Employees 393